Recent LPTX News
- Leap Therapeutics Announces $40 Million Private Placement • PR Newswire (US) • 04/11/2024 12:30:00 PM
- Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results • PR Newswire (US) • 03/18/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 02:36:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 02:36:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 02:35:49 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 02:35:24 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 02:35:23 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 02:34:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 02:34:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 02:34:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 01:41:24 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 01:39:35 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/26/2024 10:21:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 10:28:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 10:10:22 PM
- Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium • PR Newswire (US) • 01/16/2024 10:05:00 PM
- Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference • PR Newswire (US) • 01/03/2024 12:00:00 PM
- Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients • PR Newswire (US) • 01/02/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:02:47 PM
- Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium • PR Newswire (US) • 12/11/2023 09:05:00 PM
- Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference • PR Newswire (US) • 11/21/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 12:10:40 PM
- Leap Therapeutics Reports Third Quarter 2023 Financial Results • PR Newswire (US) • 11/13/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 11:51:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 06:44:15 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM